89bio

89bio, Inc. granted 49,800 stock options to four new employees under its 2023 Inducement Plan, with vesting over four years. The company focuses on therapies for liver and cardiometabolic diseases, currently in Phase 3 studies for pegozafermin, a novel FGF21 analog treatment.

DelveInsight's report on Nonalcoholic Steatohepatitis (NASH) provides insights into historical and forecasted epidemiology, market trends, current treatment practices, emerging drugs, and market size from 2019 to 2032 in the United States, EU5, and Japan. Key companies and therapies in the NASH market are highlighted, including recent developments like Aligos Therapeutics' Phase 1 data presentation.

89bio, Inc. reported a net loss of $(149.1) million in Q3 2023, advancing pegozafermin for MASH and SHTG, with Phase 3 trials initiated. The company secured Breakthrough Therapy and PRIME designations, and a manufacturing collaboration with BiBo Biopharma. Despite positive Phase 2b data, challenges include clinical development risks and reliance on pegozafermin's success.